RCMNY
Rubric Capital Management (New York) Portfolio holdings
AUM
$7.45B
1-Year Est. Return
42.53%
1 Year Est. Return
+42.53%
AUM
$7.45B
AUM Growth
+$1.23B
(+20%)
Holding
84
Top Buys
| 1 | +$117M | |
| 2 | +$86.6M | |
| 3 | +$86M | |
| 4 |
Enovis
ENOV
|
+$83.4M |
| 5 |
Newell Brands
NWL
|
+$68.1M |
Top Sells
| 1 | +$384M | |
| 2 | +$276M | |
| 3 | +$84.8M | |
| 4 |
Adaptive Biotechnologies
ADPT
|
+$72.9M |
| 5 |
COOP
Mr. Cooper
COOP
|
+$50.4M |
Sector Composition
| 1 | Healthcare | 36.98% |
| 2 | Utilities | 25% |
| 3 | Industrials | 15.36% |
| 4 | Energy | 6.88% |
| 5 | Financials | 4.63% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
76
iShares Russell 2000 ETF
IWM
$71.3B
| – | – |
0
|
|
||
77
Ovid Therapeutics
OVID
$128M
| – | – |
-478,533
|
|
||
78
PG&E
PCG
$34.8B
| – | – |
-3,600,000
|
|
||
79
SPDR S&P 500 ETF Trust
SPY
$697B
| – | – |
0
|
|
||
80
Tesla
TSLA
$1.43T
| – | – |
0
|
|
||
81
Vistra
VST
$58.8B
| – | – |
-1,424,803
|
|
||
82
State Street SPDR S&P Biotech ETF
XBI
$7.95B
| – | – |
0
|
|
||
83
Zevra Therapeutics
ZVRA
$470M
| – | – |
-1,958,318
|
|